The relationship between bisphosphonate adherence and fracture: is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial
- PMID: 20939064
- PMCID: PMC3179329
- DOI: 10.1002/jbmr.274
The relationship between bisphosphonate adherence and fracture: is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial
Abstract
Medication compliance may be a surrogate for factors that improve health outcomes such as fractures. Little is known about the size of this potential "healthy adherer" effect. We evaluated the hypothesis that compliance with placebo is associated inversely with bone loss and fractures among women participating in the Fracture Intervention Trial (FIT). Compliance with placebo and alendronate was evaluated using daily medication diaries. Women were defined as having high compliance if they took 80% or more of dispensed study medication. Change in bone mineral density (BMD) was assessed using mixed models comparing women with high versus lower compliance with placebo. Cox proportional-hazards models analyzed the association between placebo compliance and various types of fractures. Among 3169 women randomized to placebo, 82% had high compliance. Compared with women with lower placebo compliance, bone loss at the total hip was lower in compliant placebo-treated women (-0.43%/year versus -0.58%/year, p = .04). Among placebo-treated women, there were 46 hip, 110 wrist, 77 clinical vertebral, and 492 total clinical fractures. Compared with women with lower placebo compliance, women with high placebo compliance had a nonsignificant reduced risk for hip fracture [adjusted hazard ratio (HR) = 0.67, 95% confidence interval (CI) 0.30-1.45]. This trend was not observed for other fractures. Medication compliance may be a proxy for factors that confers benefit on reducing hip fracture (but not other types of fractures) independent of the effect of the medication itself. Nonrandomized studies of interventions designed to maintain or improve bone density and/or hip fracture may need to consider medication compliance as a confounder to better estimate true intervention effects.
Copyright © 2011 American Society for Bone and Mineral Research.
Figures
Comment in
-
Healthy users, healthy adherers, and healthy behaviors?J Bone Miner Res. 2011 Apr;26(4):681-2. doi: 10.1002/jbmr.384. J Bone Miner Res. 2011. PMID: 21433070 No abstract available.
Similar articles
-
Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial.J Bone Miner Res. 2004 Aug;19(8):1250-8. doi: 10.1359/JBMR.040512. Epub 2004 May 24. J Bone Miner Res. 2004. PMID: 15231011 Clinical Trial.
-
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.Lancet. 1996 Dec 7;348(9041):1535-41. doi: 10.1016/s0140-6736(96)07088-2. Lancet. 1996. PMID: 8950879 Clinical Trial.
-
Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.Lancet Diabetes Endocrinol. 2019 Dec;7(12):899-911. doi: 10.1016/S2213-8587(19)30346-8. Epub 2019 Oct 31. Lancet Diabetes Endocrinol. 2019. PMID: 31676222 Clinical Trial.
-
[Bisphosphonate treatment prevents hip fractures in 70-79 year old women with osteoporotic vertebral fractures].Ned Tijdschr Geneeskd. 2001 Jul 14;145(28):1336-8. Ned Tijdschr Geneeskd. 2001. PMID: 11484428 Review. Dutch.
-
Aging bone and osteoporosis: strategies for preventing fractures in the elderly.Arch Intern Med. 2003 Oct 13;163(18):2237-46. doi: 10.1001/archinte.163.18.2237. Arch Intern Med. 2003. PMID: 14557222 Review.
Cited by
-
Impact of Medication Adherence on Bone Mineral Density and Fracture Risk in Patients With Osteoporosis: A Systematic Review.Cureus. 2023 Jul 19;15(7):e42115. doi: 10.7759/cureus.42115. eCollection 2023 Jul. Cureus. 2023. PMID: 37602050 Free PMC article. Review.
-
Osteoporosis Medications Prevent Subsequent Fracture in Frail Older Adults.J Bone Miner Res. 2022 Nov;37(11):2103-2111. doi: 10.1002/jbmr.4693. Epub 2022 Sep 27. J Bone Miner Res. 2022. PMID: 36168189 Free PMC article.
-
Duration of Bisphosphonate Drug Holidays and Associated Fracture Risk.Med Care. 2020 May;58(5):419-426. doi: 10.1097/MLR.0000000000001294. Med Care. 2020. PMID: 31985584 Free PMC article.
-
Evaluation of the US Food and Drug Administration Sentinel Analysis Tools Using a Comparator with a Different Indication: Comparing the Rates of Gastrointestinal Bleeding in Warfarin and Statin Users.Pharmaceut Med. 2019 Feb;33(1):29-43. doi: 10.1007/s40290-018-00265-w. Pharmaceut Med. 2019. PMID: 31933271
-
Impact on Bisphosphonate Persistence and Compliance: Daily Postprandial Administration.J Bone Metab. 2019 Feb;26(1):39-44. doi: 10.11005/jbm.2019.26.1.39. Epub 2019 Feb 28. J Bone Metab. 2019. PMID: 30899723 Free PMC article.
References
-
- Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81:1013–1022. - PubMed
-
- Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int. 2007;18:271–277. - PubMed
-
- Gallagher AM, Rietbrock S, Olson M, van Staa TP. Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res. 2008;23:1569–1575. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
